glp 1 consumers Opportunities for nutrition brands in the GLP-1 boom Uncertainty still surrounds the GLP-1

These less crowded indications may offer high risk, high reward pathways for manufacturers who are looking to enter the GLP-1 arena without needing to fight for space in the competitive diabetes or obesity markets

The big headline is that oral GLP-1 options are no longer limited to treating diabetes alone, but it is still worth checking the fine print on each brand

It does not require proof of efficacy in large trials the way we typically expect from drugs, but it facilitates prescribing, and that changes things a lot, because there wont be a black market anymore

Estrogen levels become erratic and eventually decline significantly